An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1 With Inoperable Progressive/Symptomatic Plexiform Neurofibromas (PN)

M
Michael Ferguson, MD

Primary Investigator

Overview

The purpose of this study is to provide compassionate access to selumetinib capsules to patients for the treatment of NF1.

Description

This will be an open-label, single-arm, multicenter intermediate access protocol which provides treatment access to selumetinib for eligible patients with neurofibromatosis type 1 (NF1) who have inoperable, progressive/symptomatic plexiform neurofibromas (PN) without any alternative therapeutic options. All patients will continue to receive drug while they are deriving clinical benefit . Approximately 100 patients in the US will be treated as part of this protocol.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    neurofibromatosis, neurofibroma
  • Age: Between 2 Years - 100 Years
  • Gender: All

Inclusion Criteria
Diagnosis of neurofibromatosis type 1 (NF1)
Patients aged greater than or equal to 2 with onset of disease before they were 18 years
Able to swallow whole capsules
Normal cardiac function
Adequate blood pressure
The patient has exhausted all available approved therapies as appropriate for NF1
Exclusion Criteria
Prior treatment with MEK inhibitor, unless enrolling after receiving selumetinib through single patient access
Patient eligible for any ongoing clinical trials with selumetinib in the indication in question
Ophthalmological conditions
Breast-feeding
Have evidence of any other significant clinical disorder or laboratory finding that, as judged by the treating physician, makes it undesirable for the patient to participate in the study
Have any evidence of a severe or uncontrolled systemic disease, active bleeding diathesis or renal transplant
Have refractory nausea and vomiting, chronic gastrointestinal diseases, or significant bowel resection that would adversely affect the absorption/bioavailability of the orally administered study medication


Additional Information:
Participants will not be paid for their participation.

Updated on 09 Mar 2024. Study ID: 1708890674 (PHO-SHIH-ASTRA-SELUMETINI)

Connect with a study center near you

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center